Literature DB >> 9274893

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

M J George1, D R Snydman, B G Werner, J Griffith, M E Falagas, N N Dougherty, R H Rubin.   

Abstract

PURPOSE: To assess impact of cytomegalovirus (CMV) donor-recipient serostatus, infection, or disease on development of invasive fungal infection in orthotopic liver transplant recipients. PATIENTS AND METHODS: An analysis of prospectively collected data in 146 liver transplant recipients (intention to treat cohort) from 4 tertiary care, university-affiliated transplant centers in Boston (Boston Center for Liver Transplantation). Patients were observed for 1 year after transplantation for the development of CMV infection, CMV disease, CMV pneumonia, as well as for the development of opportunistic fungal infections, graft survival, and mortality. Weekly cultures were taken of urine and throat and every other week of buffy coat for CMV for 2 months, then monthly for 6 months, at 1 year, and at the time of any clinical illness. Pre- and posttransplant variables including CMV-serostatus of donor and recipient, fungal isolation from sterile body sites, fungemia, bacteremia, antibiotic use, immunosuppression, treatment for rejection, and volumes of blood products were measured.
RESULTS: Survival analysis demonstrated that 36% of patients with CMV disease developed invasive fungal disease within the first year post-transplant compared with 8% of those without CMV disease (P < 0.0001). One-year mortality in patients with invasive fungal disease was 15 of 22 (68%) compared with 23 of 124 (19%) in those without invasive fungal disease (P < 0.001). A multivariable, time-dependent analysis demonstrated that being a CMV-seronegative recipient of a CMV-seropositive donor organ (P < 0.001), having bacteremia (P = 0.001), UNOS (United Network for Organ Sharing) status 4 (need for life support measures) at transplant (P = 0.002), and volume of platelets (P = 0.002) were independently associated with invasive fungal disease. Restriction of cases of invasive fungal disease to those that occurred more than 2 weeks after transplant demonstrated an association with CMV disease (P = 0.003), bacteremia (P = 0.003), need for life support (P = 0.03), and volume of blood products transfused (P = 0.02).
CONCLUSION: CMV disease or being a CMV-seronegative recipient of a CMV-seropositive donor organ is an important predictor for invasive fungal disease following orthotopic liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274893     DOI: 10.1016/s0002-9343(97)80021-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  49 in total

Review 1.  Cytomegalovirus infection in liver transplant recipients: updates on clinical management.

Authors:  Jasmine Riviere Marcelin; Elena Beam; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.

Authors:  S S Weigt; R M Elashoff; C Huang; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; M P Keane; R Saggar; J P Lynch; D A Zisman; D J Ross; J A Belperio
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

4.  Prophylaxis of invasive mycoses in solid organ transplantation.

Authors:  Kyle P Radack; Barbara D Alexander
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

5.  Cytomegalovirus: prophylaxis, preemption, or "wait and watch".

Authors:  Shmuel Shoham
Journal:  Liver Transpl       Date:  2012-12-12       Impact factor: 5.799

Review 6.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

7.  Once weekly fluconazole for antifungal prophylaxis post-liver transplantation.

Authors:  Raelene E Trudeau; Lyndsey J Bowman; Angela R Wills; Jeffrey S Crippin; William C Chapman; Christopher Anderson
Journal:  HPB (Oxford)       Date:  2012-11-22       Impact factor: 3.647

Review 8.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

9.  A risk profile for invasive aspergillosis in liver transplant recipients.

Authors:  M Rosenhagen; R Feldhues; J Schmidt; T Hoppe-Tichy; H K Geiss
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

10.  Comparison of two methods used for monitoring low-copy cytomegalovirus infection in a patient with chronic myeloid leukemia after unrelated umbilical cord blood transplantation.

Authors:  Tomasz Dzieciatkowski; Maciej Przybylski; Agnieszka Tomaszewska; Małgorzata Rokicka; Mirosław Łuczak
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-06-08       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.